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ABSTRACT: Methotrexate (MTX) is a chemotherapeutic agent that can
cause a range of toxic side effects including gastrointestinal damage,
hepatotoxicity, myelosuppression, and nephrotoxicity and has potentially
complex interactions with the gut microbiome. Following untargeted UPLC-
qtof-MS analysis of urine and fecal samples from male Sprague−Dawley rats
administered at either 0, 10, 40, or 100 mg/kg of MTX, dose-dependent
changes in the endogenous metabolite profiles were detected. Semiquantitative
targeted UPLC-MS detected MTX excreted in urine as well as MTX and two
metabolites, 2,4-diamino-N-10-methylpteroic acid (DAMPA) and 7-hydroxy-
MTX, in the feces. DAMPA is produced by the bacterial enzyme
carboxypeptidase glutamate 2 (CPDG2) in the gut. Microbiota profiling
(16S rRNA gene amplicon sequencing) of fecal samples showed an increase in
the relative abundance of Firmicutes over the Bacteroidetes at low doses of
MTX but the reverse at high doses. Firmicutes relative abundance was positively correlated with DAMPA excretion in feces at 48 h,
which were both lower at 100 mg/kg compared to that seen at 40 mg/kg. Overall, chronic exposure to MTX appears to induce
community and functionality changes in the intestinal microbiota, inducing downstream perturbations in CPDG2 activity, and thus
may delay MTX detoxication to DAMPA. This reduction in metabolic clearance might be associated with increased gastrointestinal
toxicity.
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■ INTRODUCTION
Methotrexate (MTX, amethopterin, 4-amino-4-deoxy-N-10-
methylpteroylglutamic acid) is a folate analogue used to treat a
range of different pathologies. At doses of <15 mg/kg MTX is
widely used to treat autoimmune diseases such as rheumatoid
arthritis (RA) or psoriasis. At higher doses, usually between 15
and 1000 mg/kg,1 the drug is effective in the treatment of
neoplastic diseases, mainly for acute lymphocytic leukemia,
lymphoma, and osteosarcoma.2 At low doses, MTX shows anti-
inflammatory properties, but with prolonged use, or with high
doses, it can induce nephrotoxicity, life-threatening myelosup-
pression, gastrointestinal toxicity and hepatotoxicity.3 MTX is
metabolized in the liver by aldehyde oxidase (AO) into 7-
hydroxy-MTX (7-OH-MTX), and both the parent compound
and the metabolite are transported into cells by carrier
proteins.4,5 These metabolites can undergo polyglutamation,
and the products of this reaction inhibit dihydrofolate
reductase (DHFR) and influence folate metabolism.6 This
inhibition blocks tetrahydrofolate (THF) production from
folic acid, inhibiting purine and pyrimidine synthesis and
downstream DNA synthesis.7
The intestinal microbiota are increasingly recognized as
participating in the processing of many xenobiotics and can
also influence host responses to numerous compounds.8−12
However, our understanding of these processes remains
limited. The gut microbiota can directly participate in drug
metabolism, as occurs with MTX. Thus, following absorption
and hepatic metabolism of MTX to generate 7-OH-MTX,
these molecules are excreted into the bile and subsequently
into the gastrointestinal tract. Here, they can undergo further
biotransformation by the gut microbiota.13,14 A bacterial
enzyme, carboxypeptidase glutamate 2 (CPDG2; also referred
to as folylpolyglutamate carboxypeptidase [FGCP]), can cleave
the terminal glutamate residues of MTX and 7-OH-MTX14,15
resulting in metabolites such as 2,4-diamino-N-10-methyl-
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pteroic acid (DAMPA) and 7-hydroxy-DAMPA, respectively.16
In addition, bacterial enzymes such as p-aminobenzoyl-
glutamate hydrolase, found in E. coli, have also been shown
to catalyze this reaction.17 As these produced metabolites do
not have activity toward DHFR inhibition, glutamate
hydrolysis by CPDG2 is seen as a detoxication process.18,19
As such, CPDG2 is approved as a rescue agent in cancer
patients presenting delayed MTX clearance and acute
nephrotoxicity,2 and several clinical studies have reported
positive results for its use in this role.3,20,21 Even so, MTX and
its relatively insoluble metabolites are still presumed to
precipitate in kidneys, causing nephrotoxicity,3 as well as
causing severe gastrointestinal toxicity such as vomiting,
diarrhea, oral mucositis and, in some cases, the death of
patients.22
Therapeutic treatment can also impact the community
structure of the gut microbiota modulating its diversity and
functionality. MTX has recently been reported to inhibit the
growth of 30% of 40 representative gut bacterial strains23 and
84% of 43 bacterial isolates which had a combined relative
abundance covering 43% of the human gut microbiota.24
Studies exploring the effects of MTX on the gut microbiota
have previously focused on the anti-inflammatory role of MTX
in RA. Low doses (i.e., at or below 15 mg/week) to patients
increased the species richness and diversity of the microbiota
and reversed the perturbation of the microbiota that is often
associated with RA.25,26 In a recent study,24 MTX treatment
(10 or 50 mg/kg) of gut microflora-humanized gnotobiotic
mice decreased the relative abundance of Bacteroidetes and
increased that of the Firmicutes. As the initial targeted human
enzyme DHFR is conserved in all domains of life, such
alterations were further demonstrated as an anti-inflammatory
mechanism of MTX through potential interaction with off-
target bacterial enzymes, such as DHFR in Escherichia coli or
Lactobacillus casei.27 However, higher doses of MTX (90 mg/
kg i.p.) administrated to rats with conventional microbiota
caused mucositis and a reduction, by 705-fold, of bacterial
diversity, compared to untreated control rats.28 Using a cell
enumeration method (flow-FISH), the majority of the
alterations were seen to have occurred via a relative decrease
in anaerobes belonging to the Firmicutes, accompanied by a
relative increase in Bacteroides. This was in contrast to the
study performed in humanized gnotobiotic mice, which
showed a decrease in abundance of the phylum Bacter-
oidetes.24 In a rat model, the abundance of Bacteroides
increased by 49%, while a decrease (by 58%) was seen in a
range of bacteria including Clostridium, Ruminococcus,
Eubacterium, and Bif idobacterium.28 By perturbing the gut
microbiota, high doses of MTX may modify the abundance, or
functionality, of bacterial enzymes responsible for MTX
hydrolysis, such as CPDG2, which could result in downstream
consequences for the inactivation/detoxication of MTX into
DAMPA. Initial CPDG2 concentrations in such a bidirectional
interaction could perhaps explain differences in patient
therapeutic responses to MTX, and also toxicities. As such, a
dose-dependent two-way interaction is proposed between
MTX and the gut microbiota.
To further explore the bidirectional interaction between
MTX and the gut microbiota, the impact of drug-free dose
vehicle and three different doses of MTX (10, 40, and 100 mg/
kg) were compared in male Sprague−Dawley rats. The fecal
microbiota was characterized using 16S rRNA gene amplicon
sequencing, while the urinary and fecal metabolic phenotypes
were measured using a UPLC-MS-based metabolomic
approach. In addition, the metabolism of MTX itself was
investigated using a semiquantitative UPLC-MS assay.
■ MATERIALS AND METHODS
Chemical and Reagents
For sample preparation and UPLC-MS, LC-MS Chromasolv
acetonitrile (ACN) and methanol (MeOH) were purchased
from Honeywell (Seelze, Germany), Optima LC/MS grade
water with 0.1% formic acid (FA) and analytical reagent grade
FA were from Fisher Scientific Ltd. (Loughborough, UK). For
UPLC-MS mass accuracy and calibration, leucine enkephalin
acetate salt (hydrate) and sodium formate, as well as sodium
azide for fecal sample preparation were obtained from Sigma-
Aldrich (Gillingham, U.K.). The chemical standards, MTX,
DAMPA, 7-OH-MTX were obtained from Toronto Chemicals
(Toronto, Canada).
Study Design
As reported in detail elsewhere,29 the animal study was
performed at the University of Arizona and was approved by
the Institutional Animal Care and Use Committee (IACUC)
and in accordance with NIH guidelines. Male Sprague−
Dawley rats (N = 22), 7 to 8 weeks old, weighing between 200
and 250 g (Harlan Laboratories, Indianapolis, IN) were fed ad
libitum with a control diet (choline sufficient and amino acid-
defined) (Dyets, Bethlehem, PA) and separated into four MTX
dose-related subgroups (0, 10, 40, and 100 mg/kg, i.p.,
dissolved in 0.3 M sodium bicarbonate). The animals were
randomly placed, 12 h prior to MTX administration, into
metabolism cages. Urine samples were collected between -6
and 0 h (predose, 0 h), 6 and 12 h (12 h), 18 and 24 h (24 h),
and between 36 and 48 h (48 h); a total of 5 samples per time
point were collected. Fecal samples were collected between
−12 h and -6 h and between -6 and 0 h and combined for
analysis (predose, 0 h), between 6 and 12 h (12 h) and
between 36−48 h (48 h) postdose. Due to diarrhea in some
MTX-treated rats, it was not possible to collect all of the
postdose fecal samples (see the Results section for details).
Fecal Water Preparation for UPLC-MS Analysis
Fecal samples were defrosted and 50 mg (± 1.4 mg) were
weighed for the first biological replicate and 51 mg (± 1.3 mg)
for the second. Samples were mixed with 1 mm diameter
zirconium beads (Stratech Scientific Ltd., Ely, UK) and 1.1 mL
of H2O (3.3 mM NaN3) before being vortexed and
homogenized with a Precellys 24 bead beater (40 s per
cycle, 6500 Hz speed, 2 cycles). After 20 min of centrifugation
(17 000g), the supernatants were collected and 1.1 mL of H2O
(3.3 mM NaN3) was added to the residue, followed by an
additional step of bead beating in H2O (3.3 mM NaN3) and
centrifugation to optimize metabolite extraction. The two
supernatants were combined and 250 μL of the combined fecal
extract were transferred to a 96-well plate. For quality control
(QC) purposes, QC samples were prepared by mixing 150 μL
of each sample from the animals which had not received any
MTX to provide a pooled sample30,31 from which 250 μL were
also placed into the 96-well plate. The samples were
concentrated under a nitrogen flow for 3 h. Then 120 μL of
MeOH:H2O (1:1) were added to each sample and the plates
were centrifuged (5 min, 700g). For each centrifuged sample
100 μL were diluted with 100 μL of acidified H2O (0.1% FA)
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and transferred, in a randomized order, into 96-well plates and
placed into the LC-MS autosampler at 4 °C.
Urine Sample Preparation for UPLC-MS
Urine samples were prepared as described previously.32 Briefly,
20 μL of urine were mixed with 60 μL of MeOH and stored at
−20 °C overnight for protein removal. Samples were
centrifuged (5 min, 15,000g, 4 °C) and 25 μL of supernatant
were transferred into a 96-well plate in a randomized order.
For a QC sample a 30 μL aliquot of each control sample was
pooled. A volume of 225 μL of water was added to each
sample and the plates were centrifuged (5 min, 700 g) before
transfer to the autosampler at 4 °C.
UPLC-MS
Analysis was performed as previously described33 on a Waters
Acquity I-class UPLC system (Waters Corp., Milford, MA)
with separation on a HSS T3 1.8 μM column (2.1 mm i.d. ×
150 mm). The column temperature used was 45 °C and the
autosampler temperature was set at 4 °C. The volume of
sample injected was 5 μL. Mobile phases were water with 0.1%
FA (v/v) (solvent A) and ACN with 0.1% FA (v/v) (solvent
B), using a flow rate of 0.6 mL/min. The gradient began at
99% A, and mobile phase B increased from 1 to 55% between
0.10 s and 10 min. Between 10 and 10.65 min mobile phase B
increased to 100% and the flow rate was increased to 0.8 mL/
min, holding for 1 min as a wash step, followed by re-
equilibration of 1 min at 99% A (total run time: 12.65 min).
Prior to sample analysis, the column was conditioned with 20
QCs,30,31 and a QC was then injected every 11 samples to
enable the reproducibility and consistency of the analysis to be
monitored.
Mass spectrometry was performed using a Synapt G2-S mass
spectrometer (Waters Corp., Wilmslow, U.K) using electro-
spray ionization in positive mode (ESI+). The capillary voltage
was 1.5 kV and the source temperature was set to 120 °C. The
cone gas flow was 50 L/h and the gas used was nitrogen. The
desolvation gas temperature was 450 °C at a flow rate of 900
L/h. The nebulizer gas flow was 6 bar. Data acquisition was
carried out over the m/z range 50−1200 and data were
collected in centroid mode with a collision energy ramp of 15
to 45 eV. Leucine encephalin (MW = 556.27 Da) was used to
monitor mass accuracy with a scan collected every 60 s and a
cone voltage of 30 V. The data were collected using MassLynx
V 4.1 (Waters Corp., Manchester, U.K.). In order to perform
semitargeted analysis for MTX and its related metabolites,
calibration curves for MTX, DAMPA and 7-OH-MTX were
prepared by addition of the analytes to the fecal water (0.05,
0.5, 2, 8, 10, 16, 20 μg/mL) and urine matrices (0.1, 2, 8, 10,
16, 20, 30 μg/mL). Run order and batch effects were assessed
using the QC data.
Fecal DNA Extraction for Amplicon Sequencing
DNA extraction was carried out on fecal samples (240 mg [±
27 mg]) using the Qiagen QIAamp PowerFecal DNA kit (Mo
Bio, Carlsbad, CA, USA) according to the manufacturer’s
protocol, with the exception that the homogenization of the
samples was achieved using a Bullet Blender Strom (speed 8, 3
min) (Chembio Ltd., St Albans, UK). The Qubit dsDNA BR
assay kit (Life Technologies Ltd., Paisley, UK) was used to
quantify the extracted DNA. Dilution of each sample was
performed to obtain a final concentration of 5 ng/mL.
Amplification of the V1 and V2 regions of the 16S rRNA
gene was performed using the primers 341F (forward) and
805R (reverse), as previously reported.34 Library pooling and
quantification was carried out with NEBNext Library Quant
Kit for Illumina (New England Biolabs, Hitchin, UK) and the
pooled libraries were denatured before sequencing, which was
performed on an Illumina MiSeq platform (Illumina Inc.,
Saffron Walden, UK) by using the MiSeq Reagent Kit v3
(Illumina) and paired-end 300 bp chemistry. This 16S rRNA
gene sequence data associated with this project have been
deposited at DDBJ/ENA/GenBank under BioProject acces-
sion PRJNA599597.
Targeted UPLC-MS Analysis
The quantification of MTX, DAMPA and 7-OH-MTX by
UPLC-MS was achieved using a linear calibration curve and a
log transformation of the axis, using TargetLynx V 4.2
(Waters). The R2 for the calibration curve of each of the
standards was greater than 0.98 (Figure S1). As the fecal
samples were prepared in duplicate, concentrations of each of
the analytes were averaged. As the total volume of urine
samples collected was recorded, it was possible to calculate the
total amount of MTX excreted in the urine. However, the total
weight of the fecal samples was not recorded and so the
quantification of MTX and its metabolites excreted in feces are
reported as the mass of the analytes (μg) per 50 mg of wet
fecal sample.
Untargeted UPLC-MS Analysis
Preprocessing of the untargeted UPLC-MS analysis data was
performed using the XCMS package implemented in R,35−37
after converting the raw files into the .mzML format using
MSConvert utility of the Proteowizard package 3.0.38 Peak
picking was performed using the “centWave” method followed
by peak grouping (“nearest” method). The data sets were
normalized using median fold change method39 and a filter was
applied to remove any features presenting a coefficient of
variation higher than 20% in the QCs. Processed data were
modeled in SIMCA 14.1 (Umetrics, Umea, Sweden). Both
urine and fecal water data sets were mean-centered and log-
transformed with an offset of 20, typically used for aqueous
extracts.40 Principal component analysis (PCA) models were
used to identify outliers and observe general trends in the data.
The data sets were imported into Matlab R2018a for covariate-
adjusted projection to latent structures regression (CA-PLS-
R),41 and models were constructed adjusting for the animals,
the cohort and the replicate cofounders. The goodness-of-fit
and predictive power of each PLS-R model was assessed using
the R2Y and Q2Y values. Features having a q-value (p value
corrected by a multiple testing based on the Benjamini−
Hochberg method42 with a false discovery rate of 5%) after a
Monte Carlo Cross-Validation (MCCV, using 100 rounds and
a partitioning of 3) below 0.05 were selected for metabolite
identification. During data analysis time-related changes were
identified in the profiles of the control animals. To remove the
features that were unrelated to MTX administration an in-
house algorithm, written in R (see SI for further details) was
used to compare the list the significantly changed features in
each group and subtract those of the untreated group from the
treated groups.
Metabolite Identification
Features selected as significant according to the CA-PLS-R
models were putatively annotated using several different
approaches. Initially, the m/z and the retention times were
searched in the in-house National Phenome Centre Database
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(NPC, see acknowledgments). In addition, features were
matched with online databases using CEU Mass Mediator,43
by comparing the [M + H]+, [M + H − H2O]+, [M + Na]+, or
[M + K]+ adducts, as well as the main fragments (up to four,
Tables S1 and S2). The level of confidence for each annotation
are reported according the criteria used by the Metabolomics
Standards Initiative,44 with the addition of a subconfidence
group in the level 2 annotation. Annotation to a specific
metabolite using one orthogonal parameter (e.g., m/z values
matching to a database) or two orthogonal parameters (e.g.,
m/z values and retention time) without spiking the
corresponding authentic standard are reported as annotation
level 2b and 2a, respectively. Data-dependent acquisition
(DDA) and UPLC-MS/MS experiments (using a Xevo G2 Q-
ToF [Waters Ltd., Elstree, UK] and the same chromatographic
conditions as the original profiling) were performed on the
features tentatively annotated by this approach to support
these putative identifications. The capillary voltage was 3 kV
and the source temperature were set at 120 °C. The cone gas
flow was 150 L/h and the gas used was nitrogen. The
desolvation gas temperature was 400 °C, the desolvation gas
flow was 1000 L/h. Selected masses were fragmented with
collision energies of 10 and 30 eV, and the application of a
ramped energy (10−40 eV). Leucine encephalin was used as
the lock mass compound. The −log10 (q-value) multiplied by
the sign of the Manhattan score of the CA-PLS-R models were
used to build a heatmap of the metabolites annotated in this
way.
Data Analysis for Microbiota Profiling
The sequence reads obtained from the fecal DNA extracts were
analyzed using the Mothur package (v.1.39.5)45 based on the
MiSeq SOP pipeline.46 The Silva bacterial database (v.128)
was used to process the sequence alignment, and the
Ribosomal Database Project (v.2014) was used to classify
sequences based on the Wang approach.47 The entire data set
(number of reads generated per samples reported in Table S.1)
was exported from Mothur into R (3.4.0 through RStudio v.
1.1.463) where the package phyloseq (v.1.26.1)48 was used to
statistically explore the data. To assess β diversity and
taxonomic profile, normalization was based on the proportion
method, which scales each count in a sample by dividing by the
counts sum in this sample.48 Rarefying to the minimal depth of
reads observed in the samples (N = 4406 reads) was
performed to explore the α diversity. Illustrations of the
taxonomic profile agglomerated at family and phylum levels
were generated for each of the MTX dose groups and by
comparing pre- and post-MTX treatment. β diversity was
assessed using PCoA of Bray−Curtis dissimilarity matrix and α
diversity was assessed using the inverse Simpson index. Drug-
related effects such as diarrhea allowed only a small quantity of
feces to be collected postdose, often below the amount
required for DNA extraction for amplicon sequencing. As a
consequence, only a small number of samples were available
for some groups, thus precluding statistical analysis.
Correlation Analysis
In order to assess correlation between the excretion of
DAMPA in feces, as well as the excretion of MTX in urine
or fecal samples with the microbial taxonomic profile and the
putatively annotated metabolites, correlation matrices were
generated. Bacterial families present in more than one predose
fecal sample from three animals treated with 100 mg/kg MTX
were selected and correlated with the quantity of MTX
excreted in urine samples at 12 h postdose and with the
quantity of MTX and DAMPA excreted in fecal samples at 48
h postdose (according to the peak excretion of these
compounds in each matrix). These same families were
correlated with the putatively annotated metabolites, and
these were also correlated with the drug and its metabolites.
Spearman correlation was used, and the clustering method was
based on single linkage clustering. Significance levels for the
correlogram were calculated using the corr.mtest function in R.
■ RESULTS
A combination of semiquantitative targeted and untargeted
UPLC-MS based metabolic profiling approaches were used to
assess the biotransformation of MTX and determine its wider
biochemical impact on the urinary and fecal metabolomes of
rats. In parallel, the fecal microbiota were profiled to
characterize the bidirectional interplay between them and
MTX.
Quantification of MTX and Its Metabolites 7-OH-MTX and
DAMPA
The concentrations of MTX and its two main metabolites, 7-
OH-MTX and DAMPA, were measured in urine and feces
using semiquantitative targeted UPLC-MS (Figure 1). In urine,
MTX was the only analyte detected, at any of the time points
available for analysis (0−6, 6−12, 18−24, and 36−48 h), and
was predominantly found in the 6−12 h samples. In the feces,
animals receiving 10 mg/kg of MTX had largely excreted the
drug by 12 h postdose while those receiving doses of 40 or 100
mg/kg excreted the highest concentrations of the drug in the
36−48 h samples. DAMPA was detected in the fecal extracts
over both time-periods for the animals treated with 10 mg/kg
and mainly in the 36−48 h fecal collection for the animals
receiving 40 or 100 mg/kg. The fecal concentration of 7-OH-
MTX was negligible and was only detected in the 6−12 h
postdose samples from animals receiving 10 mg/kg of MTX
and the 36−48 h collections for the animals treated with 40
mg/kg. The fecal excretion of 7-OH-MTX was particularly low
in the animals treated with 100 mg/kg of MTX. Similarly, the
fecal concentrations of DAMPA were lower in the animals
treated with 100 mg/kg of MTX compared to the group
treated with 40 mg/kg for the 36−48 h postdose samples.
MTX Effects on Urinary Metabolite Profiles
Principal components analysis (PCA) models were built using
the endogenous urinary metabolic profiles obtained by
untargeted UPLC-MS analysis for each MTX dose to identify
sources of variation (Figure S2). A modest time-related effect
was observed in the control group, particularly by 48 h into the
study. Supervised multivariate statistical analysis using
covariate-adjusted projection to latent structures regression
(CA-PLS-R41) analysis, was also performed to illuminate the
endogenous metabolic response at each MTX dose (Figure
S3). The resulting models both fitted the data well (as
indicated by R2Y) and allowed good prediction of the data (as
determined by the Q2Y). The resulting skyline significance
representations (Figure S4) show that, the number of urinary
features significantly varying with time was more important for
the animals treated with the 100 mg/kg dose. As seen for the
PCA of the untreated (control) animals (Figure S2), time-
dependent metabolic shifts occurred in the urinary metabolic
profiles, a metabolic shift was also observed in the CA-PLS-R
models of the untreated animals, which was associated with
changes in the signal intensity of features over time (Figure
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S4). The features highlighted as significantly changed in the
control group over time were removed from consideration
when the significant features in the MTX-treated groups were
examined in order to focus on, and identify, only those
compounds changing as a result of drug treatment.
A large number of features (1651) were significantly altered
following MTX administration. Features of interest were
matched to an in-house database (based on both retention
time and m/z) and to online databases (based on m/z) (Table
S2). For a metabolite annotation to be reported it had to meet
the criteria of having two m/z values matched to values from
the database (obtained by MSE) and be confirmed by MS/MS
as well as biological plausibility. A heatmap based on the
−log10 (q-values) of these annotations was constructed from
these data (Figure 2a). Two main clusters of metabolites
emerged from this analysis, one including those that increased
over time following MTX treatment and the other including
those that decreased. Metabolites that decreased on dosing
(following CA-PLS-Regression model with a q-value < 0.05)
included ribothymidine, pimelylcarnitine, N-acetyl-arginine,
and thymidine. Among the metabolites that increased, two
subclusters can be distinguished, one includes metabolites that
showed a modest increase across all MTX-dosed animals
(creatine, N6-carbomoyl-threonyladenosine, N-methyl-4-ami-
nobenzoate, 1-methyladenosine, and xanthurenic acid), and
the other included metabolites whose excretion increased in a
dose-dependent manner such as acetylcarnosine, which closely
clustered with methionine sulfoximine, and N-acetyl-L-
glutamine, biopterin, arginine, 5-hydroxyindoleacetic acid,
creatinine, and acetylcholine.
The putative annotation of both N-methyl-4-aminobenzoate
and methionine sulfoximine is problematic as, despite good
congruence with their mass spectral properties against the
respective Metlin database entries, these are unlikely to have
been endogenous biochemicals. For example, although
methionine sulfoximine has been identified as a rare natural
product found in plants of the Connaraceae family,49 it can
also be found as a result of the reaction of NCl3 with proteins
in wheat protein in flour treated with the chemical.50 Similarly,
the putative identification of N-methyl-4-aminobenzoate, as
the most likely identity of the compound based on its MS
fragmentation properties, may also have been present in the
diet. However, in the case of this compound its structural
similarity with that of the aromatic acid portion of DAMPA has
not escaped our notice. It is possible then, that if correctly
annotated, this feature may represent either a drug impurity or
a novel metabolite of MTX produced via the N-dealkyation of
DAMPA. The reason for the apparent differences in the
relative concentrations of these two compounds in the excreta
on MTX treatment may be due therefore to factors such as
changes in xenobiotic metabolism or absorption, etc., rather
than MTX-related effects on the endogenous metabolism of
either microbiota or host.
MTX Effects on the Fecal Metabolic Profile
As was the case for urine, in the PCA models built on the fecal
metabolic profiles (Figure S5), time-related variation was also
observed. This occurred in the untreated (0 mg/kg) profiles
along principal component one. A large amount of variation
was seen in the 0−12 h and the 36−48 h samples from animals
treated with MTX. This effect was dose-dependent being more
pronounced at the higher doses.
CA-PLS-R models were also built to identify metabolic
variation occurring over time following MTX dosing (Figure
Figure 1. Quantification of MTX, 7-OH-MTX and DAMPA using UPLC-MS. (a) Excretion profile of MTX in urine, as the total amount (μg) in
the predose (0 h), 6 to 12 h (12 h), 18 to 24 h (24 h), and 36 to 48 h (48 h) urine collections. The fecal excretion of (b) MTX, (c) 7-OH-MTX,
and (d) DAMPA, in μg/50 mg of feces from the predose (0 h), 6−12 h (12 h), and 36−48 h (48 h) collections. The bar plots represent the mean
concentrations and the error bars the standard deviations. N = 5 for each time point within each dose-related group for urine. For the fecal samples
of the untreated rats, N = 6 at 0 h, N = 3 at 12 h, and N = 5 at 48 h; for the rats treated with 10 mg/kg, N = 10 at 0 h, N = 5 at 12 h, and N = 4 at 48
h; for the rats treated with 40 mg/kg, N = 9 at 0 h, N = 3 at 12 h, and N = 3 at 48 h; and for rats treated with 100 mg/kg of MTX, N = 12 at 0 h, N
= 3 at 12 h, and N = 3 at 48 h.
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S6), and, as seen for urine, these models fitted the data well
and allowed good predictions to be made (based on R2Y and
Q2Y). Like urine, a number of metabolic features (644)
changed significantly over time (after correction for multiple
testing using the false discovery rate) for each of the MTX
dose-related groups (Figure S7). The changes highlighted in
the skyline significance plot of the animals treated with the 10
and 40 mg/kg doses were similar. However, a greater increase
in biochemical perturbations and their intensity was observed
in the skyline significance plot of the animal group treated with
100 mg/kg of MTX compared to the lower dose groups. The
features significantly changing over time in the untreated
animal group were subtracted from those dosed with MTX, as
also performed for similar metabolites in urine, in order to
focus the metabolite identification only on the features affected
by MTX treatment.
In total, 24 compounds that were significantly altered by
MTX treatment were putatively annotated (Table S3). Of
these, 14 were dipeptides and one a tripeptide. Several of the
other altered metabolites were acids, namely nicotinic acid, 3-
oxocholic acid, 4-ketoretinoic acid and N-acetyl-neuraminic
acid (Figure 2b). From the cluster analysis of the altered
metabolites two main clusters of compounds were observed.
One composed of four compounds which decreased through
time in each of the MTX dose groups, and another group
composed of the features which increased. Within the cluster
of compounds increasing, some were observed to do so only in
rats treated with 100 mg/kg of MTX (especially the dipeptides
containing leucine or isoleucine, as well as glycyl-phenyl-
alanine, prolyl-asparagine and prostaglandin B3), while others
were significantly increased in animals receiving 40 mg/kg.
Thus, in the case of animals treated with 40 mg/kg of MTX,
leucyl-glutamine, 4-ketoretinoic acid, N-acetyl-neuraminic acid,
and glutamate increased over time even more than was the
case of those dosed at 100 mg/kg (particularly leucyl-
glutamine and 4-ketoretinoic acid). Similarly, serinyl-proline,
nicotinic acid, histidinyl-proline, and 3-oxocholic acid
decreased even more dramatically in the fecal extracts from
animals treated with 40 mg/kg.
MTX Effects on the Fecal Microbiota
The effect of MTX on the fecal microbiota Bray−Curtis PCoA
analysis was used to assess β-diversity within the data set
(Figure S8). No, or only small, differences were observed when
comparing the PCoA plots of the predose and the 6−12 h
postdose time points for all the dose-related groups. Greater
variance was seen 36−48 h postdose compared to the predose
time point across all groups; however, this was also observed in
the control group. This dissimilarity was particularly marked
for the fecal samples of the animals treated with 100 mg/kg. α
Diversity was also assessed using the Inverse Simpson index.
The averaged α diversity is reported in Table S4. The α
diversity of the untreated animals (0 mg/kg) was stable over
time. However, for the animals dosed at 10 mg/kg, the α
diversity of their fecal samples had increased in the 6−12 h
post MTX-dose samples before decreasing by 36−48 h post
MTX-dose. In comparison, the α diversity of the fecal samples
of the animals administered with 40 mg/kg MTX decreased at
6−12 h postdose and stabilized at 36−48 h postdose, which
was not the case for the animals that received 100 mg/kg of the
drug, where α diversity progressively decreased over the 48 h
following MTX administration.
As both β and α diversity displayed a stronger shift in the
36−48 h collection point, the taxonomic profiles of each of the
MTX dose-related groups were aggregated and plotted for the
pre- and 48 h postdose periods only (Figure 3). The fecal
microbiota of the animal group dosed with 100 mg/kg of MTX
provided the most notable microbial shift, albeit based on only
a limited number of samples (N = 2) obtained due to diarrhea
(see caption to Figure 3), with a striking increase in the relative
abundance of Peptostreptococcaceae and Porphyromonadaceae
and a decrease in the relative abundance of Ruminococcaceae.
This alteration appears to have been dose dependent as it was
not seen in the animals treated with 0 or 10 mg/kg of MTX
but was visible in animals receiving 40 mg/kg (again, based on
N = 3) of the drug. A microbial shift was also observed over
time for the vehicle-only treated group (0 mg/kg), with an
increase in the relative abundance of unclassified Firmicutes
and a decrease in the relative abundance of Erysipelotrichaceae.
This change was also noted in animals that received 10 and 40
mg/kg of MTX, but not those treated with 100 mg/kg of
MTX, where the reverse occurred. Also, a decrease in the
Figure 2. Heatmaps of the metabolites putatively annotated in the urine samples (a) and in the fecal samples (b), and significantly influenced by
MTX treatment. Color represents the −log10 (q-value) multiplied by the Manhattan sign of the CA-PLS-R models. Red represents an increase of
the feature over time and blue indicates a decrease. N = 5 for each time point within each dose-related group in urine. For the fecal samples of the
untreated rats, N = 6 at 0 h, N = 3 at 12 h, and N = 5 at 48 h; for the rats treated with 10 mg/kg, N = 10 at 0 h, N = 5 at 12 h, and N = 4 at 48 h; for
the rats treated with 40 mg/kg, N = 9 at 0 h, N = 3 at 12 h, and N = 3 at 48 h; and for the rats treated with 100 mg/kg of MTX, N = 12 at 0 h, N =
3 at 12 h, and N = 3 at 48 h.
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relative abundance of Bacteroidaceae, unclassified Bacteroidales,
Bacteroidetes, and Mollicutes was observed for the MTX-treated
rats, particularly the 100 mg/kg-dosed animals, compared to
the control group (0 mg/kg).
Taxonomic profiles of the animals over time following MTX
administration were also assessed at phylum level (Figure 4). A
different trend was observed in response to the lowest and
highest doses of MTX in changes at this level with, at the 10
mg/kg dose, a decrease in the relative abundance of
Bacteroidetes and an increase in the relative abundance of
Firmicutes was observed. Conversely, at doses of 40 mg/kg
there was an increase in the relative abundance of
Bacteroidetes and a decrease in the relative abundance of
Firmicutes, which was exaggerated in the animals treated with
100 mg/kg of MTX.
Figure 3. Family level taxonomic profiles (relative abundance) of the fecal microbiota of the rodents in each of the MTX dose-related groups pre-
and post-MTX treatment (0 h and 36−48 h, respectively). For the untreated animals, N = 4 at 0 h and N = 3 at 48 h; for the animals which
received a dose of 10 mg/kg, N = 8 at 0 h and N = 3 at 48 h; for the animals which received a dose of 40 mg/kg, N = 8 at 0 h and N = 4 at 48 h; for
the animals which received a dose of 100 mg/kg, N = 9 at 0 h and N = 2 at 48 h.
Figure 4. Taxonomic profiles of the fecal samples of the rodents representing the relative abundance of the phyla in each of the MTX dose-related
group pre- and post-MTX treatment (0 and 48 h, respectively). For the untreated animals, N = 4 at 0 h and N = 3 at 48 h; for the animals which
received a dose of 10 mg/kg, N = 8 at 0 h and N = 3 at 48 h; for the animals which received a dose of 40 mg/kg, N = 8 at 0 h and N = 4 at 48 h; for
the animals which received a dose of 100 mg/kg, N = 9 at 0 h and N = 2 at 48 h.
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Correlation Analysis
Correlation analyses between the bacterial families present in
the fecal samples of the 100 mg/kg dose animals prior to MTX
treatment, with the quantity of MTX measured in urine at 12 h
and in feces at 36−48 h, as well as the quantity of DAMPA
excreted in feces samples between 36 and 48 h, were
undertaken (Figure 5). The excretion of DAMPA in feces
was positively correlated with the predose relative abundance
of Prevotellaceae, Anaeroplasmataceae, Ruminococcaceae, and
Lactobacillaceae, and negatively correlated with the predose
relative abundance of Deferribacteraceae and Coriobacteriaceae.
Other significant bacterial-metabolite linkages included a
negative correlation between Deferribacteraceae and the
bacterial families Veillonellaceae, Prevotellaceae, Pasteurellaceae,
Acidaminococcaceae, and Anaeroplasmataceae (five families
showing positive correlations with one another) and
Ruminococcaceae (Figure 5). Similarly, the Coriobacteriaceae
were negatively correlated with Prevotellaceae, Anaeroplasma-
taceae, and Ruminococcaceae (Figure 5).
Correlation analyses between the bacterial families present
in the fecal samples of these high dose animals prior to MTX
treatment, with the relative intensities of the putatively
annotated metabolites measured in urine and in feces at 36−
48 h were also performed (Figure 6). The relative abundances
of Prevotellaceae and Anaeroplasmataceae, previously found to
be positively correlated with the excretion of DAMPA in feces
at 48 h (Figure 5), were found positively correlated with
glutamate excreted in feces and 5-hydroxyindole acetic acid in
urine at 48 h (Figure 6). Similarly, the relative abundances of
Def feribacteraceae and Coriobacteriaceae, previously found to be
negatively correlated with the excretion of DAMPA in feces at
48 h (Figure 5), were found positively correlated with
glutamate excreted in feces and 5-hydroxyindole acetic acid
in urine at 48 h (Figure 6). The relative abundances of
Prevotellaceae and Anaeroplasmataceae were negatively corre-
lated with the relative abundances of Def feribacteraceae and
Coriobacteriaceae in both analyses (Figures 5 and 6). Finally,
the relative abundance of Lactobacillaceae, previously found to
be positively correlated with the excretion of DAMPA in feces
at 48 h (Figure 5), was also positively correlated with the
amount of the putatively annotated N-methyl-4-aminoben-
zoate excreted in urine at 48 h. In addition, the relative
abundance of Ruminococcaceae were also positively correlated
with the peak putatively annotated as methionine sulfoximine
excreted in urine at 48 h (Figure 6). However, as with all
putative assignments, caution needs to be exercised with this
structure which has, as noted above, previously only been
positively identified in plants,49 or flour treated with NCl3.
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Correlation analyses between the quantity of MTX
measured in urine at 12 h and in feces at 36−48 h, as well
as the quantity of DAMPA excreted in feces samples between
36 and 48 h, with the relative intensities of the putatively
annotated endogenous metabolites present in the urine and
fecal samples of these high dose animals prior to MTX
treatment, were also made (Figure S9). The excretion of MTX
in feces at 48 h was found to negatively correlate with prolyl-
asparagine in feces and 5-hydroxyindoleacetic acid in the urine
samples of the predose animals. At 48 h 5-hydroxyindoleacetic
acid was found to be positively correlated with the relative
abundances of Prevotellaceae and Anaeroplasmataceae pretreat-
ment and negatively correlated with the relative abundances of
Deferribacteraceae and Coriobacteriaceae pretreatment (Figure
Figure 5. Correlogram integrating the bacteria present pre-MTX-dose in the 100 mg/kg dose animals fecal samples at family level with MTX
concentration measured in urine at 6−12 h and in feces at 36−48 h, as well as the quantity of DAMPA excreted in feces samples at 36−48 h. This
Figure shows only the significant correlations only (p < 0.05), highlighting positive correlations for DAMPA excreted in feces with Prevotellaceae,
Anaeroplasmataceae, Ruminococcaceae, and Lactobacillaceae and a negative correlation with Deferribacteraceae and Coriobacteriaceae (N = 3 animals).
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6), themselves showing the same correlative patterns with the
excretion of DAMPA in feces at 48 h (Figure 5). The excretion
of MTX in urine at 12 h was found to be positively correlated
with the excretion of 4-ketoretinoic acid and nicotinic acid in
the feces samples of the predose animals (Figure S9).
■ DISCUSSION
As indicated in the Introduction, in clinical use MTX has
proved to be an effective treatment in diseases such as
rheumatoid arthritis (RA), where it is a first line therapy, and
in many cancers.1,2 But therapeutic responses can be variable
and unpredictable and drug related (and dose limiting)
toxicity3,29 (to liver, kidney and GI tract as well as
myelosuppression) is also observed. The rat has proved to
be a popular model species for studying the effects of MTX in
vivo, including toxicity,51 and appears also to show some
agreement with humans with respect to the pharmacokinetics
of both MTX and 7-OH-MTX.51
A combination of targeted and untargeted UPLC-MS-based
metabolic profiling approaches were used to assess the
biotransformation of MTX and determine its wider bio-
chemical impact on the urinary and fecal metabolomes of rats.
In parallel, the fecal microbial profiles were defined to
characterize the bidirectional interplay between MTX and
the microbiota.
The untargeted UPLC-MS results highlighted a number of
biochemical pathways that appeared to be affected by MTX,
particularly at the 100 mg/kg dose. For example, MTX inhibits
dihydrofolate reductase (DHFR), and therefore the production
of the tetrahydrofolate, required for purine and pyrimidine
synthesis, affects DNA synthesis (as well as the trans-
methylation of phospholipids and proteins52). MTX also
inhibits thymidine synthesis when the free plasma concen-
tration of MTX exceeds 10 nM.53 This is reflected in the
observed reduction in the excretion of the pyrimidine
nucleosides ribothymidine and thymidine after MTX admin-
istration. In contrast, the administration of 100 mg/kg MTX
increased the excretion of purine nucleoside-related com-
pounds, such as N6-carbamoyl-threonyladenosine and 1-
methyl-adenosine, which is likely to be a consequence of the
increased adenosine release previously reported as an anti-
inflammatory property of MTX.54 In addition, the amounts of
xanthine, a purine base produced following the degradation of
adenosine monophosphate to uric acid, increased in the feces
following MTX exposure.
The urinary excretion of creatinine and its precursor creatine
increased following MTX treatment (Figure 2). Creatine was
previously found to be increased in the urine samples when the
metabolic profile of urine from this study was studied by 1H
NMR spectroscopy.55 Interestingly, arginine, a precursor of
creatine and a related metabolite N-acetylglutamine, also
increased in the urine following MTX intake. Urinary N-acetyl-
arginine was reduced, possibly due either to increased
catabolism to produce arginine, or reduced consumption of
Figure 6. Correlogram integrating the bacteria present pre-MTX-dose in the fecal samples at family level with putatively annotated compounds
excreted in urine and feces samples at 36−48 h. This Figure shows only significant correlations (p < 0.05) showing positive correlations between
the relative abundances of Prevotellaceae, Anaeroplasmataceae, and glutamate in feces and 5-hydroxyindole acetic acid in urine at 48 h, and negative
correlation of the same metabolites with the relative abundance of Deferribacteraceae and Coriobacteriaceae. N = 3 animals.
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arginine. Other urinary metabolites previously shown to be
altered using 1H NMR spectroscopic analysis following MTX
treatment were methylamine, dimethylamine, TMAO, for-
miminoglutamic acid, alanine, phenylacetylglycine, succinate,
citrate, 3-indoxyl sulfate, hippurate, and formate.55 MTX-
induced elevations in the urinary excretion of creatine could
also reflect disruptions to energy metabolism, as creatine is
required for the production of phosphocreatine and thus ATP.
The potential for MTX treatment to impact on energy
metabolism has been previously been suggested55 and
hypothesized to be related to reduced nutrient intake. This
has been explained by MTX-induced gut epithelial loss and
inflammation, morphological damage and malabsorption,
previously reported in rats.29,56 Naruhashi et al.56 showed
the disruption of intestinal peptide transporters, such as
PEPT1, following MTX exposure, which may explain
alterations in the fecal excretion of dipeptides following the
40 and 100 mg/kg MTX doses, reflecting an impairment in
protein digestion or absorption. Increased concentrations of
the metabolite 5-hydroxyindoleacetic acid, a metabolite of
serotonin and gastroenteritis marker,57 in urine following MTX
treatment could be explained by gastrointestinal toxicity.
Similarly, in the fecal samples 4-ketoretinoic acid, involved in
the maintenance of the epithelial tissue,58 and N-acetyl-
neuraminic acid, found in the gut mucus membrane (among
others), were also found to be increased in amount in fecal
extracts following MTX treatment. Other metabolites related
to gut function and gut morphological toxicity were also
perturbed by MTX intake. Fecal carnitine and urinary
acetylcholine, which have both been shown to influence bile
acid transport,59−62 were found to increase, while the bile acid
3-oxocholic acid was found to decrease in amount in fecal
extracts, suggesting that targeted analysis for this class of
metabolite might be warranted in future studies.
Fecal glutamate excretion increased over time following
MTX treatment, which may have arisen by its release from the
degradation of MTX during metabolism to DAMPA via the
bacterial enzyme CPDG2. The semiquantification of MTX, 7-
OH-MTX and DAMPA in fecal water samples identified two
distinct dose dependent effects. Thus, at the lowest MTX dose
(10 mg/kg) both the drug and its metabolite 7-OH-MTX were
excreted in the feces at 12 h while the microbial metabolite
DAMPA was excreted between 12 to 48 h. At the higher doses
(40 or 100 mg/kg) MTX and DAMPA excretion were delayed
until 48 h. The MTX excretion profile was found to be in
agreement with a previous report of the same study using an
alternative MS platform.29 Surprisingly, DAMPA excretion
following the 100 mg/kg MTX dose was lower than that
measured during the same time period for the animals
administered with 40 mg/kg MTX. Saturation of CPDG2,
the enzyme that cleaves glutamate from MTX to produce
DAMPA, may explain this observation. Alternatively, a shift in
the microbial community structure following the highest dose
of MTX may reduce CPDG2 production or activity. Indeed,
the fecal microbial profile was modulated by MTX with the
notable changes having occurred by 48 h postdose being most
pronounced at the 100 mg/kg dose. Interestingly, at the
phylum level, changes observed between the pretreatment
microbial profile and the microbial profile of the fecal samples
collected at 48 h were different when the dose administrated
was 10 mg/kg rather than 100 mg/kg of MTX. The microbial
shift induced by 10 mg/kg of MTX included a decrease in
Bacteroidetes and an increase in the Firmicutes. This was
consistent with previous findings.24 Such changes in bacterial
populations were then reversed at the 100 mg/kg dose level
potentially explaining the recently reported dose related
antimicrobial effect of MTX.24
Correlative studies show that DAMPA in feces was
positively associated with Prevotellaceae, Anaeroplasmataceae,
Ruminococcaceae, and Lactobacillaceae and was negatively
associated with the relative abundance of Def feribacteraceae
and Coriobacteriaceae (Figure 5). Interestingly, the relative
abundances of Prevotellaceae and Anaeroplasmataceae as well as
Def feribacteraceae and Coriobacteriaceae show the same
correlative pattern with the excretion of glutamate in feces
and the excretion of 5-hydroxyindole acetic acid in urine at 48
h (Figure 6). This could mean that the bacterial enzyme
CPDG2, which cleaves MTX into DAMPA and glutamate,
might be produced by bacteria from the families Prevotellaceae
and Anaeroplasmataceae. However, 5-hydroxyindole acetic acid
was found to be negatively correlated with the excretion of
MTX in feces at 48 h (Figure S9). The excretion of the
metabolite 4-ketoretinoic acid, involved in maintaining the gut
epithelial layer, was found to be positively correlated with the
excretion of MTX in urine at 12 h (Figure S9).
Prevotellaceae and Anaeroplasmataceae were strongly corre-
lated with Ruminococcaceae and Lactobacillaceae, all of them
positively correlating with DAMPA excretion in fecal samples.
The relative abundances of these species also correlated with
those of the Veillonellaceae, Pasteurellaceae, and Acidaminococ-
caceae. However, as shown in Figure 4, the relative abundance
of the phylum Firmicutes decreased following a dose of 100
mg/kg of MTX. This demonstrates that higher abundances of
certain bacteria, mainly from the phylum Firmicutes, prior to
administration of MTX were positively associated with higher
concentrations of DAMPA in fecal samples. These bacteria
could be producing the bacterial enzyme CPDG2, responsible
for DAMPA production through MTX metabolism. Because
the number of animals used in this study were kept to a
minimum it is clear that further studies will be required to
confirm these results. However, identifying the bacterial strains
that can produce CPDG2 and determining the expression/
activity of this enzyme in the gut microbiome of patients prior
to MTX administration could enable an individual’s risk of
MTX toxicity/reduced efficacy to be estimated prior to drug
therapy. Clearly, in making this conjecture we recognize that it
depends on limited data derived from a study conducted in a
small number of normal rats rather than patients. Although the
rat is thought to represent a suitable model for human with
respect to MTX metabolism and toxicity51 it may be less
suitable in terms of the gut microbiota, and the extrapolation of
the present findings to clinical decision making clearly requires
caution. However, if on investigation the results do translate to
human disease, then patients identified as having low relative
abundances of, e.g., Prevotellaceae and Anaeroplasmataceae
could be identified before treatment was initiated. These
patients could then either be proactively supplemented with
CPDG2 to mitigate against MTX toxicity rather than it being
used retroactively once toxicity develops as is current practice,2
or actively monitored so that treatment to limit MTX toxicity
could be begun promptly.
■ CONCLUSIONS
When DAMPA, a nontoxic metabolite of MTX produced by
the bacterial enzyme CPDG2,13,14 was quantified in fecal
samples, its excretion positively correlated with the relative
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abundances of the Prevotellaceae and Anaeroplasmataceae.
These bacterial families were themselves positively correlated
with glutamate, which suggests that they are able to produce
the CPDG2 enzyme. While further analysis is required to
validate this hypothesis, determining the abundance of these
bacteria in patients to inform subsequent chemotherapeutic
treatment may contribute to the personalization of this
strategy. Conversely, high doses of MTX perturbed the gut
microbial community, increasing the relative abundance of
Bacteroidetes and decreasing that of the Firmicutes.
Perturbations in endogenous metabolites involved in gut
disorder and gut epithelium or mucus maintenance such as 5-
hydroxyindoleacetic acid, 4-ketoretinoic acid, and N-neura-
minic acid were assumed to reflect toxicity. Chronic exposure
to MTX could modify the composition and functional capacity
of the microbiome with a subsequent impact on its ability to
produce CPDG2 and detoxify the drug. A clearer under-
standing of this relationship in humans may have the potential
to enhance the effectiveness of MTX therapy and minimize
toxic outcomes.
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(36) Tautenhahn, R.; Böttcher, C.; Neumann, S. Highly Sensitive
Feature Detection for High Resolution LC/MS. BMC Bioinf. 2008, 9
(1), 504.
(37) Benton, H. P.; Want, E. J.; Ebbels, T. M. D. Correction of Mass
Calibration Gaps in Liquid Chromatography-Mass Spectrometry
Metabolomics Data. Bioinformatics 2010, 26 (19), 2488−2489.
(38) Kessner, D.; Chambers, M.; Burke, R.; Agus, D.; Mallick, P.
ProteoWizard: Open Source Software for Rapid Proteomics Tools
Development. Bioinformatics 2008, 24 (21), 2534−2536.
(39) Veselkov, K. A.; Vingara, L. K.; Masson, P.; Robinette, S. L.;
Want, E.; Li, J. V.; Barton, R. H.; Boursier-Neyret, C.; Walther, B.;
Ebbels, T. M.; Pelczer, I.; Holmes, E.; Lindon, J. C.; Nicholson, J. K.
Optimized Preprocessing of Ultra-Performance Liquid Chromatog-
raphy/Mass Spectrometry Urinary Metabolic Profiles for Improved
Information Recovery. Anal. Chem. 2011, 83 (15), 5864−5872.
(40) Rocke, D. M.; Durbin, B. Approximate Variance-Stabilizing
Transformations for Gene-Expression Microarray Data. Bioinformatics
2003, 19 (8), 966−972.
(41) Posma, J. M.; Garcia-Perez, I.; Ebbels, T. M. D.; Lindon, J. C.;
Stamler, J.; Elliott, P.; Holmes, E.; Nicholson, J. K. Optimized
Phenotypic Biomarker Discovery and Confounder Elimination via
Covariate-Adjusted Projection to Latent Structures from Metabolic
Spectroscopy Data. J. Proteome Res. 2018, 17 (4), 1586−1595.
(42) Benjamini, Y.; Hochberg, Y. Controlling the False Discovery
Rate: A Practical and Powerful Approach to Multiple Testing. Journal
of the Royal Statistical Society: Series B (Methodological) 1995, 57 (1),
289−300.
(43) Gil de la Fuente, A.; Godzien, J.; Fernańdez Loṕez, M.;
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